FMR LLC held its stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,331,989 shares of the company’s stock at the end of the first quarter. FMR LLC owned approximately 5.22% of SCYNEXIS worth $3,676,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in SCYNEXIS by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of SCYNEXIS during the first quarter valued at about $154,000. Finally, Private Advisor Group LLC purchased a new position in shares of SCYNEXIS during the first quarter valued at about $555,000. 48.53% of the stock is currently owned by institutional investors.
Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) opened at 1.66 on Friday. The firm’s market capitalization is $44.36 million. SCYNEXIS, Inc. has a one year low of $1.52 and a one year high of $5.51. The firm has a 50-day moving average price of $1.74 and a 200 day moving average price of $2.30.
COPYRIGHT VIOLATION NOTICE: “Fmr LLC Has $3,676,000 Position in SCYNEXIS, Inc. (NASDAQ:SCYX)” was first posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/scynexis-inc-nasdaqscyx-stake-held-by-fmr-llc-updated-updated.html.
Several research analysts have recently issued reports on the company. HC Wainwright set a $14.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Wednesday. Roth Capital set a $9.00 price target on SCYNEXIS and gave the company a “buy” rating in a research report on Monday, August 7th. Zacks Investment Research upgraded SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Wednesday, August 2nd. ValuEngine upgraded SCYNEXIS from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Finally, Aegis reiterated a “buy” rating on shares of SCYNEXIS in a research report on Tuesday, May 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $10.22.
In other SCYNEXIS news, Director David C. Hastings bought 20,000 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was acquired at an average cost of $1.75 per share, with a total value of $35,000.00. Following the purchase, the director now owns 20,000 shares in the company, valued at approximately $35,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have bought 40,000 shares of company stock valued at $66,600. Company insiders own 3.91% of the company’s stock.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.